MAP2K7 and melanoma: Specifically, there is an urgent demand for new therapies aimed at patients with BRAF wild-type tumors who advance despite immunotherapy and those with BRAF-mutant melanoma who progress on both immunotherapy and BRAF-MEK targeted treatments.